title: Successful treatment of Hodgkin lymphoma in second trimester of pregnancy: feasibility of ABVD regimen.
abstract: A 34-year-old woman at 18 weeks of gestation during her third pregnancy was diagnosed with Hodgkin lymphoma stage IVA. She was treated with standard ABVD and showed good response. After three-and-a-half courses of ABVD, she spontaneously delivered a healthy baby girl at 41 weeks of gestation. She continued chemotherapy after delivery. A total of six courses of ABVD were given. Complete remission was obtained and has continued for 6 months post chemotherapy. Neither mother nor child developed any infections during the observation period. The child has also shown no physiological or developmental abnormalities. Here, we describe the feasibility and safety of the ABVD regimen for the treatment of Hodgkin lymphoma, and discuss the optimal treatment strategy.
authors.affiliation: Department of Internal Medicine, Nihon University School of Medicine, Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-Ku, Tokyo, 179-0072, Japan. iriyama.noriyoshi@nihon-u.ac.jp.
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Iriyama
authors.affiliation: Department of Internal Medicine, Nihon University School of Medicine, Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-Ku, Tokyo, 179-0072, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Horikoshi
authors.affiliation: Department of Internal Medicine, Nihon University School of Medicine, Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-Ku, Tokyo, 179-0072, Japan.
authors.forename: Toshitake
authors.initials: T
authors.lastname: Tanaka
authors.affiliation: Department of Hematology and Rheumatology, Nihon University School of Medicine, Itabashi Hospital, 30-1 Oyaguchi Kami-cho, Itabashi-Ku, Tokyo, 173-8610, Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Hirabayashi
authors.affiliation: Department of Internal Medicine, Nihon University School of Medicine, Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-Ku, Tokyo, 179-0072, Japan.
authors.forename: Hitomi
authors.initials: H
authors.lastname: Kodaira
authors.affiliation: Department of Hematology and Rheumatology, Nihon University School of Medicine, Itabashi Hospital, 30-1 Oyaguchi Kami-cho, Itabashi-Ku, Tokyo, 173-8610, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hatta
authors.affiliation: Department of Hematology and Rheumatology, Nihon University School of Medicine, Itabashi Hospital, 30-1 Oyaguchi Kami-cho, Itabashi-Ku, Tokyo, 173-8610, Japan.
authors.forename: Jin
authors.initials: J
authors.lastname: Takeuchi
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin